Long non-coding RNA TPT1-AS1 promotes angiogenesis and metastasis of colorectal cancer through TPT1-AS1/NF90/VEGFA signaling pathway

Zhang, Yiyun; Sun, Jiangyun; Qi, Yuan; Wang, Yimin; Ding, Yu; Wang, Kun; Zhou, Qingxin; Wang, Jingxuan; Ma, Fei; Zhang, Jianguo; Guo, Bin

doi:10.18632/aging.103016

Cited by 36 publications

(28 citation statements)

References 23 publications

(32 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TPT1-AS1 (TPT1 antisense RNA 1) is located on chromosome 13 and has been reported to promote proliferation and metastasis in a variety of cancers [27,28]. Interestingly, our finding of TPT1-AS1 as a potential therapeutic target for OC is corroborated by the study of Wu et al, who recently showed that TPT1-AS1 induces OC tumor growth and metastasis [29].…”

Section: Discussionsupporting

confidence: 81%

Identification and validation of a five-lncRNA signature for predicting survival with targeted drug candidates in ovarian cancer

et al. 2021

View full text Add to dashboard Cite

The dysregulation of long non-coding RNAs (lncRNAs) plays a crucial role in ovarian cancer (OC). In this study, we screened out five differentially expressed lncRNAs (AC092718.4, AC138035.1, BMPR1B-DT, RNF157-AS1, and TPT1-AS1) between OC and normal ovarian based on TCGA and GTEx RNA-seq databases by using Kaplan-Meier analysis and univariate Cox, LASSO, and multivariate Cox regression. Then, a risk signature was constructed, with 1, 3, 5-year survival prediction accuracy confirmed by ROC curves, and an online survival calculator for easier clinical use. With lncRNA-microRNA-mRNA regulatory networks established, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses were performed, suggesting the involvement of a variety of cancer-related functions and pathways. Finally, five candidate small-molecule drugs (thioridazine, trifluoperazine, loperamide, LY294002, and puromycin) were predicted by Connectivity Map. In conclusion, we identified a 5-lncRNA signature of prognostic value with its ceRNA networks, and five candidate drugs against OC.

show abstract

Section: Discussionsupporting

confidence: 81%

Identification and validation of a five-lncRNA signature for predicting survival with targeted drug candidates in ovarian cancer

et al. 2021

View full text Add to dashboard Cite

show abstract

“… 81 lncRNA TPT1-AS1 directly binds nuclear factor 90 (NF90) and induces the interplay between NF90 and the VEGFA mRNA, thus enhancing VEGFA mRNA stability and facilitating CRC angiogenesis and metastasis. 82 Moreover, LINC00346 can bind to the ZNF655 mRNA by its Alu elements, thereby promoting the degradation of the ZNF655 mRNA in a Staufen1-mediated mRNA decay manner. Furthermore, ANKHD1 targets LINC00346 and elevates its stability.…”

Section: Angio-lncrs: Mechanisms Of Action In Cancersmentioning

confidence: 99%

Long non-coding RNAs and circular RNAs in tumor angiogenesis: From mechanisms to clinical significance

Liu

Yan

et al. 2021

Molecular Therapy - Oncolytics

View full text Add to dashboard Cite

Long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) execute a wide array of functions in physiological and pathological processes, including tumor progression. Angiogenesis, an elaborate multistep process driving new blood vessel formation, accelerates cancer progression by supplying nutrients and energy. Dysregulated lncRNAs and circRNAs can reportedly impact cancer progression by influencing angiogenesis. However, the expanding landscape of lncRNAs and circRNAs in tumor progression-dependent angiogenesis remains largely unknown. This review summarizes the major functions of angiogenic lncRNAs (Angio-LncRs) and angiogenic circRNAs (termed Angio-CircRs) and their cancer mechanisms. Moreover, we highlight the commonalities of lncRNAs and circRNAs in epigenetic, transcriptional, and post-transcriptional regulation as well as illustrate how Angio-LncRs and Angio-CircRs induce cancer onset and progression. We also discuss their potential clinical applications in diagnosis, prognosis, and anti-angiogenic therapies.

show abstract

“…TPT1-AS1 can promote angiogenesis and metastasis of colorectal cancer (14). Up-regulation of TPT1-AS1 expression can promote tumorigenesis and metastasis of epithelial ovarian cancer (15).…”

Section: Discussionmentioning

confidence: 99%

Guizhi Fuling pills inhibit the proliferation, migration and invasion of human cutaneous malignant melanoma cells by regulating the molecular axis of LncRNA TPT1-AS1 / miR-671-5p

Zhang

2020

Cell Mol Biol (Noisy-le-grand)

View full text Add to dashboard Cite

The current research was aimed to explore the effects of Guizhi Fuling Pills on the proliferation, migration and invasion of human cutaneous malignant melanoma cells and its regulation on the molecular axis of LncRNA TPT1-AS1 / miR-671-5p. Human cutaneous malignant melanoma cells A375 were cultured in vitro and randomly divided into Con group, Guizhi Fuling pills-L group, Guizhi Fuling pills-M group, Guizhi Fuling pills-H group, Guizhi Fuling pills-H + pcDNA group, Guizhi Poria pills-H + pcDNA-TPT1-AS1 group. MTT was used to detect cell proliferation. The Transwell cell test was used to detect cell migration and invasion. qRT-PCR was used to detect the expression of TPT1-AS1 and miR-671-5p. The dual-luciferase report experiment verified the targeting relationship of TPT1-AS1, miR-671-5p. Western blot was used to detect the expression of Ki-67, PCNA, MMP-2 and MMP-9. Compared with Con group, Guizhi Fuling Pills could inhibit cell proliferation, migration and invasion (p<0.05), and also inhibit the expression of Ki-67, PCNA, MMP-2, MMP-9, TPT1-AS1 (p<0.05), promote the expression of miR-671-5p (p<0.05)., and the differences between the indexes of Guizhi Fuling Pill-L group, Guizhi Fuling Pill-M group and Guizhi Fuling Pill-H group were statistically significant (p<0.05). The dual-luciferase report experiment confirmed that TPT1-AS1 could target and bind to miR-671-5p and could regulate the expression and activity of miR-671-5p. Overexpression of TPT1-AS1 could reduce the inhibitory effect of Guizhi Fuling Pills on proliferation, migration and invasion of A375 cells. Guizhi Fuling Pill may reduce the proliferation, migration and invasion of human cutaneous malignant melanoma cells by down-regulating the expression of TPT1-AS1 and up-regulating the expression of miR-671-5p.

show abstract

Long non-coding RNA TPT1-AS1 promotes angiogenesis and metastasis of colorectal cancer through TPT1-AS1/NF90/VEGFA signaling pathway

Cited by 36 publications

References 23 publications

Identification and validation of a five-lncRNA signature for predicting survival with targeted drug candidates in ovarian cancer

Identification and validation of a five-lncRNA signature for predicting survival with targeted drug candidates in ovarian cancer

Long non-coding RNAs and circular RNAs in tumor angiogenesis: From mechanisms to clinical significance

Guizhi Fuling pills inhibit the proliferation, migration and invasion of human cutaneous malignant melanoma cells by regulating the molecular axis of LncRNA TPT1-AS1 / miR-671-5p

Contact Info

Product

Resources

About